Review Maps CBD Absorption Across All Administration Routes, Highlighting Transdermal Potential

Oral CBD has 6-19% bioavailability due to hepatic first-pass metabolism and gastric instability. Inhaled routes provide rapid onset but raise pulmonary concerns. Transdermal delivery bypasses hepatic degradation, offers improved bioavailability and targeted effects. The review compiled a literature-based ADME profile highlighting that individual responses to CBD vary significantly.

Narrative review examining transdermal CBD administration, skin barrier strategies, and bioavailability across different routes. Compiled literature-based ADME study. Reviewed endocannabinoid system function and CBD regulatory landscape across Europe, UK, USA, and Australia.

Most CBD consumers use oral products without understanding that only 6-19% of their dose reaches the bloodstream. Understanding bioavailability across routes helps consumers and clinicians choose the most effective and efficient delivery method.

As CBD products proliferate worldwide with inconsistent regulation, understanding pharmacokinetics becomes essential for both consumers and healthcare providers. Transdermal delivery could solve the fundamental problem of poor oral bioavailability that limits CBD efficacy.

Narrative review without systematic methodology. Transdermal CBD clinical data is limited. Individual variability makes generalizations difficult. Regulatory landscape changes rapidly and review may not reflect current status.